Evidence map›Paper›PMID 39651308›Full record

ArticlebioRxiv : the preprint server for biology2025

Early adipose tissue wasting in a novel preclinical model of human lung cancer cachexia.

Deena B Snoke, Jos L van der Velden, Emma R Bellafleur, Jacob S Dearborn, Sean M Lenahan, Alexandra E Beal, Reem Aboushousha, Skyler C J Heininger, Jennifer L Ather, Madeleine M Mank and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Deena B SnokeDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0003-2189-9441
Jos L van der VeldenDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0002-2451-3180
Emma R BellafleurDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.
Jacob S DearbornDepartment of Surgery, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0001-8894-1574
Sean M LenahanDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0003-3222-970X
Alexandra E BealDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.
Reem AboushoushaDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.
Skyler C J HeiningerDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.
Jennifer L AtherDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0003-0484-5599
Madeleine M MankDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.
Hailey SarauskyDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.
Daniel StephensonDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.
Julie A ReiszDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-7296-4963
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-2258-6490
Devdoot MajumdarDepartment of Surgery, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0002-2541-3851
Thomas P AhernDepartment of Surgery, University of Vermont College of Medicine, Burlington, VT.
Kaiwen XuDepartment of Computer Science, Vanderbilt University and Vanderbilt University Medical Center, Nashville, TN, USA.
Kim L SandlerDepartment of Radiology, Vanderbilt University and Vanderbilt University Medical Center, Nashville, TN, USA.
Bennett A LandmanDepartment of Computer Science, Vanderbilt University and Vanderbilt University Medical Center, Nashville, TN, USA.
Yvonne M W Janssen-HeiningerDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0002-2735-8745
Matthew E PoynterDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0002-7578-4570
David J SewardDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT.
Michael J TothDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.ORCID 0000-0003-0668-1911

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Kimberly Luebbers · 2017 to 2026
$51.6M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Karen Eileen Peterson · 2010 to 2026
$20.3M
Michigan Mouse Metabolic Phenotyping CenterU2CDK110768 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELIAS, CAROL FUZETI · 2016 to 2021
$6.2M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Novel Integrative Approach for the Early Detection of Lung Cancer using Repeated MeasuresR01CA253923 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANDMAN, BENNETT A., MALDONADO, FABIEN · 2021 to 2025
$3.4M
Glutaredoxin, Glutathione Metabolism and Lung CancerR01CA273238 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Yvonne M. W. Janssen-Heininger · 2023 to 2026
$2.1M
Skeletal Muscle Atrophy and Dysfunction in Human CancerR01AR065826 · NIAMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TOTH, MICHAEL J · 2016 to 2021
$2.1M
Development of a clinically relevant mouse model of lung cancer cachexia to study pathoetiology and therapeutic strategiesR21CA283492 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TOTH, MICHAEL J · 2023 to 2024
$392k
STK11 loss of function and anti-PD-1 therapy resistance in KRAS-driven lung adenocarcinomaR21CA280266 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SEWARD, DAVID JOSEPH · 2023 to 2024
$392k
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA253923NCI NIH HHS R01 CA273238NCI NIH HHS R21 CA280266NCI NIH HHS R21 CA283492NHLBI NIH HHS T32 HL076122NIAMS NIH HHS R01 AR065826NIDDK NIH HHS P30 DK089503NIDDK NIH HHS U2C DK110768NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

Cancer cachexia (CC), a syndrome of skeletal muscle and adipose wasting, reduces responsiveness to therapies and increases mortality. There are no approved treatments for CC, which may relate to discordance between pre-clinical models and human CC. To address the need for clinically relevant models of lung CC, we generated inducible, lung epithelial cell specific

Indexed as

inflammationlipolysisLung neoplasmsorganoidsskeletal muscle

Identifiers

PMID39651308
PMCPMC11623500

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.